Back to top
more

Amedisys (AMED)

(Delayed Data from NSDQ)

$97.75 USD

97.75
409,224

+0.17 (0.17%)

Updated Jul 25, 2024 04:00 PM ET

After-Market: $97.84 +0.09 (0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Compared to Estimates, Amedisys (AMED) Q2 Earnings: A Look at Key Metrics

The headline numbers for Amedisys (AMED) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Amedisys (AMED) Q2 Earnings and Revenues Top Estimates

Amedisys (AMED) delivered earnings and revenue surprises of 8.20% and 2.05%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Quest Diagnostics Incorporated (DGX) Soars to 52-Week High, Time to Cash Out?

Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Here's Why Amedisys (AMED) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

AMED or USPH: Which Is the Better Value Stock Right Now?

AMED vs. USPH: Which Stock Is the Better Value Option?

Encompass Health (EHC), Piedmont Expand Ties to Serve Georgia

Encompass Health (EHC) expands its partnership with Piedmont to better serve Georgians with the Walton Rehabilitation Hospital.

AMED vs. USPH: Which Stock Is the Better Value Option?

AMED vs. USPH: Which Stock Is the Better Value Option?

Here's Why Amedisys (AMED) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

AMED vs. USPH: Which Stock Should Value Investors Buy Now?

AMED vs. USPH: Which Stock Is the Better Value Option?

UnitedHealth (UNH), Amedisys Clear Merger Hurdle With Asset Sale

By selling these assets, UnitedHealth (UNH) and Amedisys aim to avoid potential monopoly issues and ensure a smoother merger process.

Why Amedisys (AMED) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Amedisys (AMED) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Is Amedisys (AMED) Up 5.5% Since Last Earnings Report?

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Amedisys (AMED) Q1 Earnings Surpass Estimates, Margins Rise

Amedisys (AMED) tops on revenue and earnings estimates in the first quarter of fiscal 2024.

Compared to Estimates, Amedisys (AMED) Q1 Earnings: A Look at Key Metrics

The headline numbers for Amedisys (AMED) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Amedisys (AMED) Q1 Earnings and Revenues Surpass Estimates

Amedisys (AMED) delivered earnings and revenue surprises of 1.98% and 1.21%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Premium Growth Propels Humana (HUM) to Easy Q1 Earnings Beat

Humana (HUM) bumps up individual Medicare Advantage membership growth guidance.

Amedisys (AMED) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Amedisys (AMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why Amedisys (AMED) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Should You Buy HCA Healthcare (HCA) Ahead of Q1 Earnings?

HCA Healthcare's (HCA) first-quarter results are likely to reflect increased admissions and patient days.

Quest Diagnostics (DGX) Beats Q1 Earnings and Revenue Estimates

Quest Diagnostics (DGX) delivered earnings and revenue surprises of 9.68% and 3.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Why Amedisys (AMED) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Is Amedisys (AMED) Down 2.5% Since Last Earnings Report?

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

How Amedisys (AMED) Stock Stands Out in a Strong Industry

Amedisys (AMED) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.